← All trials
NCT01314937
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2011
- Primary completion
- Jul 1, 2013
- Completion date
- Jul 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 1760
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- McGill UniversityLead sponsor
- McGill UniversityOverall official - principal investigator
- McGill UniversityCollaborator
- World Health OrganizationCollaborator
- Thrasher Research FundCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- McGill UniversityReponsible party - principal investigator
- Asociación Civil Selva AmazónicaOverall official - principal investigator
- Asociación Civil Selva AmazónicaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.